TransEnterix, Inc. (TRXC) Short Interest Down 2.1% in January

TransEnterix, Inc. (NYSEAMERICAN:TRXC) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 36,343,750 shares, a drop of 2.1% from the January 15th total of 37,107,265 shares. Based on an average daily volume of 1,781,222 shares, the short-interest ratio is presently 20.4 days. Currently, 20.4% of the shares of the stock are sold short.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of TransEnterix by 9.1% in the fourth quarter. BlackRock Inc. now owns 13,722,308 shares of the medical instruments supplier’s stock valued at $31,014,000 after buying an additional 1,146,566 shares during the last quarter. Vanguard Group Inc raised its position in shares of TransEnterix by 13.5% in the third quarter. Vanguard Group Inc now owns 8,455,056 shares of the medical instruments supplier’s stock valued at $49,039,000 after buying an additional 1,003,091 shares during the last quarter. Vanguard Group Inc. raised its position in shares of TransEnterix by 13.5% in the third quarter. Vanguard Group Inc. now owns 8,455,056 shares of the medical instruments supplier’s stock valued at $49,039,000 after buying an additional 1,003,091 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of TransEnterix in the third quarter valued at about $30,149,000. Finally, First Trust Advisors LP raised its position in shares of TransEnterix by 818.2% in the fourth quarter. First Trust Advisors LP now owns 1,035,426 shares of the medical instruments supplier’s stock valued at $2,340,000 after buying an additional 922,659 shares during the last quarter.

TRXC opened at $2.60 on Tuesday. TransEnterix has a 52-week low of $1.29 and a 52-week high of $6.98.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of TransEnterix from a “sell” rating to a “hold” rating in a report on Friday, November 9th. LADENBURG THALM/SH SH raised shares of TransEnterix from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Friday, November 9th.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2019/02/12/transenterix-inc-trxc-short-interest-down-2-1-in-january.html.

TransEnterix Company Profile

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Featured Article: How are institutional investors different from individual investors?

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply